Replies to post #60259 on NorthWest Biotherapeutics Inc (NWBO)

[TZOR]

The Company has received a letter from the staff of The NASDAQ Stock Market LLC ("Nasdaq") indicating that the Nasdaq Staff reviewed certain stock issuances by the Company to Cognate, and determined that those issuances did not comply with Nasdaq rules 5635(c) and (d), as described in a Form 8-K being filed by the Company today. The Company is currently in discussions with the Nasdaq Staff about two potential approaches to remedy the non-compliance with these rules, and the Company intends to take the appropriate steps to address the issues raised by the Nasdaq Staff as quickly as possible.

After a quick search the NASDAQ rules mentioned pertain to equity compensation and private placements.

See link

http://nasdaq.cchwallstreet.com/NASDAQTools/PlatformViewer.asp?searched=1&selectednode=chp_1_1_4_3_8_26&CiRestriction=5635&manual=%2Fnasdaq%2Fmain%2Fnasdaq-equityrules%2F


My favorite part of the press release is this part

The Company has received updated data from the ongoing follow-up of patients in the Phase I portion of the DCVax-Direct trial. To date, 20 of the 40 patients have exceeded 12 months overall survival ("OS"), 13 of the 40 patients exceed 18 months OS, at least 10 of those 13 patients (with 2 of the 13 currently unknown) are still alive at OS times up to 29 months to date, with the majority having exceeded 20 months.

I bet those patients are quite happy about NWBO

[H2R]

Thanks TC Trader! Finally something of interest for the stock.

My favorite part:

The Company has reached conceptual agreement with three different sets of parties, in regard to three different combination treatments, for three different cancers in three different Phase II trials. These involve leading participants in the immunotherapy field. The Company and these parties are now completing the agreements and budgets, and pursuing regulatory approval for the agreed upon trials.

The Company is establishing a Scientific Advisory Board (“SAB”). The Company has reached agreement with the initial members of the SAB, including leading experts in immunotherapy and oncology from both the US and Europe. The initial members are in the process of completing their internal institutional approvals.